| Description |
1 online resource |
| Contents |
Front Cover; Personalized Immunosuppression in Transplantation; Copyright Page; Contents; Preface; List of Contributors; 1 Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring; 1.1 Introduction; 1.2 Calcineurin Inhibitors; 1.2.1 Cyclosporine A; 1.2.2 Tacrolimus; 1.3 Antimetabolite Drug; 1.4 Mammalian Target of Rapamycin Inhibitors; 1.4.1 Sirolimus (Rapamycin); 1.4.2 Everolimus (RAD001); 1.5 Conclusions; References; 2 Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants; 2.1 Introduction |
|
2.2 Methods for Therapeutic Drug Monitoring of Immunosuppressants2.3 Cyclosporine Monitoring: Trough or C2 Monitoring?; 2.4 Limitations of Immunoassays Used for Cyclosporine Monitoring; 2.5 Limitations of Immunoassays Used for Tacrolimus Monitoring; 2.6 Limitations of Immunoassays Used for Sirolimus Monitoring; 2.7 Limitations of Immunoassays Used for Everolimus Monitoring; 2.8 Limitations of Immunoassays Used for Mycophenolic Acid Monitoring; 2.9 Conclusions; References |
|
3 Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug mo ... 3.1 Introduction; 3.2 Evolution of Non-Immunoassay Methods for Immunosuppressants; 3.3 LC-MS/MS Methods for Analysis of Immunosuppressants; 3.3.1 Preanalytical Variable: Specimens; 3.3.2 Preanalytical Variable: Specimen Collection; 3.3.3 Preanalytical Variable: Drug-Drug Interactions; 3.3.4 Preanalytical Variable: Genetic Polymorphisms; 3.3.5 Preanalytical Variable: Clinical Status of the Patient; 3.3.6 Preanalytical Variable: Pregnancy |
|
3.3.7 Analytical Step: Specimen Preparation3.3.8 Analytical Step: Reagents; 3.3.9 Analytical Step: Solvents; 3.3.9.1 Proficiency testing; 3.4 Limitation of Mass Spectrometric Methods; 3.4.1 Ion Suppression/Enhancement; 3.4.1.1 Cross talk and in-source fragmentation; 3.4.1.2 Isobaric interferences; 3.5 Turnaround Time; 3.6 Conclusions; References; 4 Monitoring free mycophenolic acid concentration: Is there any clinical advantage?; 4.1 Introduction; 4.2 Monitoring Free Drug Concentration; 4.3 Monitoring Free (Unbound) Fraction of Cyclosporine |
|
4.4 Monitoring Free (Unbound) Fraction of Tacrolimus and Sirolimus4.5 Mycophenolic Acid: A Brief Introduction; 4.6 Rationale for Therapeutic Drug Monitoring of Mycophenolic Acid; 4.6.1 Serum Protein Binding of Mycophenolic Acid; 4.6.2 Conditions That Increase Free Mycophenolic Acid Level; 4.6.3 Clinical Utility of Monitoring Free Mycophenolic Acid; 4.6.4 Drug-Mycophenolic Acid Interaction; 4.6.5 Analytical Methods for Determination of Free Mycophenolic Acid; 4.7 Conclusion; References; 5 Pharmacogenomics aspect of immunosuppressant therapy; 5.1 Introduction; 5.2 Individual Genes |
| Summary |
Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring provides coverage of the various approaches to monitoring immunosuppressants in transplant patients, including the most recently developed biomarker monitoring methods, pharmacogenomics approaches, and traditional therapeutic drug monitoring. The book is written for pathologists, toxicologists, and transplant surgeons who are involved in the management of transplant patients, offering them in-depth coverage of the management of immunosuppressant therapy in transplant patients wi |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Vendor-supplied metadata |
| Subject |
Immunosuppressive agents.
|
|
Transplantation immunology.
|
|
Immunosuppressive Agents -- therapeutic use
|
|
Transplantation Immunology
|
|
Immunosuppressive Agents
|
|
MEDICAL -- Pharmacology.
|
|
Immunosuppressive agents
|
|
Transplantation immunology
|
| Form |
Electronic book
|
| Author |
Oellerich, Michael, editor.
|
|
DasGupta, A. (Amitava), editor.
|
| LC no. |
2015937699 |
| ISBN |
9780128011331 |
|
0128011335 |
|
